Programme Thesis
VitaDAO funds early-stage longevity research projects that bridge the 'Valley of Death' between academic discovery and commercial development, using decentralized governance and IP-NFTs to democratize funding and align incentives. It exists to accelerate human healthspan extension by supporting high-risk, high-reward biomedical research that traditional venture capital and pharma often overlook.
Selection Criteria
- Scientific merit: novelty, rigor, and potential impact on longevity/healthspan
- Commercial viability: clear path to IP protection, licensing, or product development
- Alignment with longevity goals: direct or indirect relevance to aging biology, age-related diseases, or healthspan extension
- Team capability: expertise, track record, and ability to execute the proposed research
- Feasibility: realistic timeline, budget, and milestones for the proposed work
- Community fit: openness to decentralized governance, IP-NFT model, and VitaDAO's collaborative ethos
Past Winners / Cohort Profiles
- Autophagy activation studies at Newcastle University
- Genetic therapies from Oisín Biotechnologies
- Mitochondrial health research projects
- Gero (AI longevity startup, partnered with Chugai Pharmaceutical for >$1B)
- Turn.bio (licensing agreements >$300M with HanAll Biopharma)
- Rubedo Life Sciences ($40M Series A, senolytic drugs in human trials)
- VitaLabs fellowship projects (4 selected via quadratic governance from 70 applications)
Ideal Candidate Fingerprint
An early-career or independent researcher with a novel, well-validated hypothesis in longevity or aging biology, who is open to tokenized IP and decentralized governance. The ideal applicant has a clear translational path (e.g., drug target, biomarker, or therapeutic platform), strong preliminary data, and a collaborative mindset to engage with VitaDAO's community and Pods.
Recommended Framing
Eniola should frame the CCT model as a novel computational framework for preventing reward-memory encoding in addiction, which has direct implications for age-related cognitive decline and neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) where aberrant reward signaling and memory consolidation are implicated. By highlighting the model's mathematical rigor, Bayesian validation, and potential to identify new drug targets for both addiction and aging-related cognitive disorders, Eniola can position his work as a cross-disciplinary longevity-relevant platform. Additionally, his DeSci platforms (IMPRINT, TOPOLOGIX, GATE) demonstrate the kind of open, decentralized research infrastructure that VitaDAO values.
Watch Out
The applicant's primary focus is addiction neuroscience, not direct longevity research, which may require careful framing to demonstrate relevance. The pre-patent stage (provisional patent Q3 2026) may complicate IP-NFT integration, as VitaDAO typically funds projects with clearer IP ownership. The applicant is an independent researcher without a PhD or institutional affiliation, which could be seen as a risk factor for grant execution and credibility, though VitaDAO's early-stage focus may mitigate this.